Dynavax Technologies Corporation [NASDAQ: DVAX] jumped around 0.55 points on Friday, while shares priced at $10.07 at the close of the session, up 5.78%. The company report on February 19, 2021 that Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine.
— Approval follows positive opinion by European Committee for Medicinal Products for Human Use.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
— Approval based on safety and immunogenicity results from three Phase 3 clinical trials.
Dynavax Technologies Corporation stock is now 126.29% up from its year-to-date (YTD) trading value. DVAX Stock saw the intraday high of $11.00 and lowest of $9.52 per share. The company’s 52-week high price is 12.44, which means current price is +130.96% above from all time high which was touched on 02/01/21.
Compared to the average trading volume of 5.93M shares, DVAX reached a trading volume of 8668532 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Dynavax Technologies Corporation [DVAX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DVAX shares is $16.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DVAX stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Dynavax Technologies Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 07, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $12 to $14. The new note on the price target was released on August 03, 2020, representing the official price target for Dynavax Technologies Corporation stock. Previously, the target price had yet another raise to $14, while Evercore ISI analysts kept a Outperform rating on DVAX stock.
The Average True Range (ATR) for Dynavax Technologies Corporation is set at 0.92, with the Price to Sales ratio for DVAX stock in the period of the last 12 months amounting to 27.89. The Price to Book ratio for the last quarter was 15.98, with the Price to Cash per share for the same quarter was set at 1.70.
How has DVAX stock performed recently?
Dynavax Technologies Corporation [DVAX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.67. With this latest performance, DVAX shares gained by 96.68% in over the last four-week period, additionally plugging by 55.16% over the last 6 months – not to mention a rise of 105.09% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DVAX stock in for the last two-week period is set at 65.57, with the RSI for the last a single of trading hit 64.26, and the three-weeks RSI is set at 65.68 for Dynavax Technologies Corporation [DVAX]. The present Moving Average for the last 50 days of trading for this stock 6.46, while it was recorded at 9.79 for the last single week of trading, and 6.10 for the last 200 days.
Dynavax Technologies Corporation [DVAX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Dynavax Technologies Corporation [DVAX] shares currently have an operating margin of -338.44 and a Gross Margin at +27.47. Dynavax Technologies Corporation’s Net Margin is presently recorded at -433.29.
Return on Total Capital for DVAX is now -60.86, given the latest momentum, and Return on Invested Capital for the company is -78.52. Return on Equity for this stock declined to -427.72, with Return on Assets sitting at -62.29. When it comes to the capital structure of this company, Dynavax Technologies Corporation [DVAX] has a Total Debt to Total Equity ratio set at 2,647.59. Additionally, DVAX Total Debt to Total Capital is recorded at 96.36, with Total Debt to Total Assets ending up at 78.65. Long-Term Debt to Equity for the company is recorded at 2,610.93, with the Long-Term Debt to Total Capital now at 95.03.
Reflecting on the efficiency of the workforce at the company, Dynavax Technologies Corporation [DVAX] managed to generate an average of -$660,606 per employee. Receivables Turnover for the company is 5.59 with a Total Asset Turnover recorded at a value of 0.14.Dynavax Technologies Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.50 and a Current Ratio set at 4.40.
Earnings analysis for Dynavax Technologies Corporation [DVAX]
With the latest financial reports released by the company, Dynavax Technologies Corporation posted -0.44/share EPS, while the average EPS was predicted by analysts to be reported at -0.33/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DVAX.
Insider trade positions for Dynavax Technologies Corporation [DVAX]
There are presently around $847 million, or 78.50% of DVAX stock, in the hands of institutional investors. The top three institutional holders of DVAX stocks are: FEDERATED HERMES, INC. with ownership of 11,946,800, which is approximately 9.135% of the company’s market cap and around 0.10% of the total institutional ownership; BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, holding 10,895,773 shares of the stock with an approximate value of $109.72 million in DVAX stocks shares; and STATE STREET CORP, currently with $109.64 million in DVAX stock with ownership of nearly -6.169% of the company’s market capitalization.
Positions in Dynavax Technologies Corporation stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 63 institutional holders increased their position in Dynavax Technologies Corporation [NASDAQ:DVAX] by around 7,366,554 shares. Additionally, 78 investors decreased positions by around 11,408,298 shares, while 35 investors held positions by with 65,305,877 shares. The mentioned changes placed institutional holdings at 84,080,729 shares, according to the latest SEC report filing. DVAX stock had 12 new institutional investments in for a total of 156,900 shares, while 33 institutional investors sold positions of 2,526,885 shares during the same period.